Protocol 156-03-236: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure

Trial Profile

Protocol 156-03-236: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure

Completed
Phase of Trial: Phase III

Latest Information Update: 28 May 2018

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Therapeutic Use
  • Acronyms EVEREST
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 28 May 2018 Chronic-heart-failure and Heart-failure are retained according to inclusion criteria.
    • 11 Apr 2018 Results (n=4133) published in the American Journal of Cardiology.
    • 15 Nov 2017 Results of sudden cardiac death risk after hospitalisation presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top